Immunovant, Inc.
IMVT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $3 | $3 | $3 | $4 |
| - Cash | $1 | $1 | $1 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $2 | $3 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.73 | -0.71 | -0.64 | -0.76 |
| % Growth | -2.8% | -10.9% | 15.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |